PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “MORPHOLINES”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1984

Evaluation of morpholine, 3-morpholinone, and N-substituted morpholines in the rat hepatocyte primary culture/DNA repair test.

Morpholine and a series of morpholine derivatives were assayed for the potential to induce DNA repair in the rat hepatocyte primary culture/DNA repair assay. Morpholine did not induce DNA repair at dose concentrations which were not toxic (0.0001-0.1 mg/ml). Two animal metabolites of morpholine, N- methylmorpholine oxide and N- hydroxymorpholine , also did not induce DNA repair at the non-toxic concentrations tested (0.0001-10 mg/ml and 0.0001-1 mg/ml, respectively). A putative metabolite of morpholine, 3- morpholinone , was inactive (0.001-10 mg/ml) and a polyurethane foam catalyst, N- butylmorpholine (0.0001-0.1 mg/ml) was also inactive. The chemical intermediate N- hydroxyethylmorpholine induced DNA repair in the dose range 1-5 mg/ml. It was concluded that genotoxicity of substituted morpholines is a function of the substituent moiety rather than morpholine itself.

Animals↗
PubMed1997

Quantitation of 4-cyclohexyl-2-hydroxy-3-(3-methylsulfanyl-2- [2-[(morpholine-4-carbonyl)amino]-3-phenylpropionylamino]propi onylamino ) butyric acid isopropyl ester (CP-80,794), a renin inhibitor, and its hydrolytic cleavage metabolite 2-[(morpholine-4-carbonyl)amino]-3-phenylpropionic acid (CP-84,364) in dog and human plasma by high-performance liquid chromatography.

Simple and precise high-performance liquid chromatographic (HPLC) assays were developed and validated for the determination of a renin inhibitor (RI), 4-cyclohexyl-2-hydroxy-3- (3-methylsulfanyl-2-[2-[(morpholine-4-carbonyl)amino]- 3-phenylpropionylamino]propionylamino)butyric acid isopropyl ester (CP-80,794, I), and its hydrolytic cleavage metabolite, 2-[(morpholine-4-carbonyl)amino]-3-phenylpropionic acid (CP-84,364, II) in dog and human plasma. The internal standard for I, CP-83,092 (III, a carbon-substituted derivative of I) and analyte were extracted by liquid-liquid extraction using n-butyl chloride, cleaved to form a fragment containing a primary amine, and subsequently fluorescently derivatized for measurement by HPLC. Samples were analyzed by reversed-phase HPLC using a Waters C18 column with fluorescence detection at 390 nm excitation/440 nm emission. The quantitation limit of I was 10 ng/ml and the calibration curve was linear over the range of 0.01-1.0 microgram/ml (r2 > 0.99). In dog and human plasma, intra- and inter-assay precision ranged from 2.3 to 16% and 3.0 to 18%, respectively. The average recoveries were similar (> or = 63%) for both I and III and the upper limit of quantification of I can be as high as 4 micrograms/ml. The internal standard for II, CP-96,452 (IV, a methoxy derivative of II) and analyte were extracted by anion-exchange solid-phase extraction and subsequent liquid-liquid extraction using methyl tert.-butyl ether. Samples were analyzed by reversed-phase HPLC using a Waters C18 column with ultraviolet detection at 214 nm. The quantitation limit of II was 20 ng/ml and the calibration curve was linear over the range of 0.02-2.0 micrograms/ml (r2 > 0.99). In dog and human plasma, intra- and inter-assay precision ranged from 2.6 to 13.0% and 1.8 to 20.0%, respectively. The average recoveries were similar (> or = 75%) for both II and IV and the upper limit of quantification of II can be as high as 20 micrograms/ml. The methods described have been successfully applied to the quantification of I and II in about 5000 dog and human plasma samples over a 2 year period.

Animals↗
PubMed2001

[Synthesis and pharmacologic action of chiral fomocaine ((4-[2-methyl-3-(morpholin-4-yl)propyl)benzyl)-phenyl-ether and (4-(1-methyl-3-(morpholin-4-yl)propyl]benzyl)-phenyl-ether). 13. Synthesis of new compounds with local anesthetic action].

The syntheses of two chiral fomocaines namely rac ((4-[2-methyl-3-(morpholin-4-yl)propyl]-benzyl)-phenyl-ether (O/G 3) and rac (4-[1-methyl-3-(morpholin-4-yl)propyl]benzyl)-phenyl-ether) (O/G 5) are reported. These compounds are part of a new research program concerning the relation between chirality and local anaesthetic activity in the group of fomocaines. The yield over five steps is in the range of 9% (O/G 3) up to 19.2% (O/G 5). The racemates were resoluted via the diastereomeric salts formed with (+)- or (-)-camphersulfonic acid. The chromatographic resolution in analytical scale is successful using a Daicel OD-column. The enantiomers are stable. The surface anaesthesia of the racemates as well as of the enantiomeres is weaker in comparison with fomocaine. The rate of tissue irritation is higher. The LD50 (mouse i.v.) is in the range between 290-390 mg/kg, while fomocaine shows a LD50 value of 175 mg/kg.

Anesthetics, Local↗
PubMed1998

The Molecular Structure of Morpholine and the Morpholine-H2O Complex Determined by FT Microwave Spectroscopy.

The rotational spectrum of the morpholine-H2O complex was measured and assigned using a Balle-Flygare type FT microwave spectrometer. Rotational, quartic centrifugal distortion, and 14N quadrupole coupling constants were determined, and a N ellipsis H-O hydrogen-bonded structure was found to be consistent with the derived molecular parameters. Additionally, the rotational spectrum of the 13C and 15N isotopomers of the morpholine monomer were measured in natural abundance to determine its r0 structure and a partial heavy atom rs structure. Copyright 1998 Academic Press.

Journal Article↗
PubMed2004

Facile route to 3,5-disubstituted morpholines: enantioselective synthesis of O-protected trans-3,5-bis(hydroxymethyl)morpholines.

[reaction: see text] (3R,5R)-1 R1 & R2 = TBDPS, (3S,5R)-2 R1 = Bn,R2 = TBDPS, (3S,5S)-3 R2 & R2 = Bn. trans-3,5-Bis(benzyl/tert-butyldiphenylsilyloxymethyl)morpholines, promising candidates for the C(2)-symmetric class of chiral reagents, were prepared with excellent optical purity. A key step in the synthesis is the coupling of a serinol derivative with 2,3-O-isopropylideneglycerol triflate or its equivalent. This methodology was extended to the synthesis of chiral trans-3-(benzyloxymethyl)-5-(tert-butyldiphenylsilyloxymethyl)morpholine, a potentially useful chiral building block.

Journal Article↗
PubMed1990

The biodegradation of morpholine in river water and activated sludge.

The ability of microorganisms in a wide range of river waters and activated sludges to degrade the heterocyclic compound morpholine was determined by die-away tests and also by most probable number counts of the morpholine degrading microbes. All activated sludges were capable of morpholine degradation but the rate at which degradation occurred could not be related to the type of influent treated. Nearly all river waters contained morpholine degrading microbes which could degrade morpholine in die-away tests. Generally, biodegradation of morpholine occurred more rapidly the further down stream the sample was taken. Morpholine degradation rates could not, however, be related to the immediate severity of pollution (as measured by National Water Council (NWC) classification) at any sampling site. It may be that morpholine degradation rate is related to the cumulative effects of successive discharges of polluting effluents rather than the immediate effect of any particular discharge. Clearly, the capacity to degrade morpholine exists in rivers and activated sludges from sewage works; in practice, however, the rates of degradation observed are very low and it is unlikely that significant morpholine biodegradation generally occurs in these systems.

Journal Article↗
PubMed1994

Degradation of morpholine by Mycobacterium aurum MO1.

When Mycobacterium aurum MO1 was grown with morpholine, the release of ammonia into the supernatant was proportional to the disappearance of morpholine, showing that this compound was mineralized. MO1 was able to grow in high concentrations of morpholine but accumulation of ammonia inhibited growth and degradation of morpholine. Immobilization of bacterial cells in carrageenan gel beads showed that morpholine degradation in these conditions began earlier and was faster than in free culture. One of the two branches of the lower pathway of morpholine biodegradation was induced while the other branch was inhibited in the presence of morpholine. Strain MO1 grew on heterocyclic compounds similar to morpholine, demonstrating that MO1 is able to degrade heterocyclic compounds containing nitrogen atoms (piperidine and pyrrolidine). Compounds containing sulphur or oxygen atoms or compounds with double bonds were not degraded.

Ammonia↗
PubMed1998

Morpholin-2-yl-phosphinic acids are potent GABA(B) receptor antagonists in rat brain.

The pharmacological properties of morpholin-2-yl-phosphinic acids were evaluated on GABA(B) receptors. In rat neocortical slices maintained in Mg2+-free Krebs medium, baclofen, a GABA(B) receptor agonist, produced a concentration-dependent depression of the frequency of spontaneous discharges with an EC50 of 14 +/- 5.5 microM, which was antagonised reversibly by the morpholin-2-yl-phosphinic derivatives. The order of potency was 3-[(3S,6R)-6-[(cyclohexylmethyl)hydroxyphosphinoylmethyl- morpholin-3-yl]benzoic acid (CGP 76290A) (pA2 = 7.1 +/- 0.05) > its enantiomer 3-[(3R,6S)-6-[(cyclohexylmethyl)hydroxyphosphinoylmethyl]-++ +morpholin-3-yl]benzoic acid (CGP 76291A) (pA2 = 6.8 +/- 0.1) > cyclohexylmethyl-[(2R',5S')-5-(3-nitrophenyl)-morpholin-2-++ +ylmethyl]phosphinic acid (CGP 71978) (pA2 = 6.5 +/- 0.05) > cyclohexylmethyl-[(2R,5S)-5-phenyl-morpholin-2-ylmethyl++ +]phosphinic acid (CGP 71980) (pA2 = 6.3 +/- 0.15) > its enantiomer cyclohexylmethyl-[(2S,5R)-5-phenyl-morpholin-2-ylmethyl++ +]phosphinic acid (CGP 71979) (pA2 = 5.8 +/- 0.1). An open chain analogue of CGP 76290A, CGP 56999A (3-[1(R)-[(3-cyclohexylmethyl-hydroxyphosphinoyl)-2(S)-hydro xypropyl-amino]-ethyl]benzoic acid lithium salt) gave a pA2 of 6.6 +/- 0.2. In GABA(B) receptor binding assays, CGP 71982 (the racemic mixture of CGP 76290A and CGP 76291A), CGP 76290A, CGP 76291A, CGP 71978, CGP 71980 and CGP 71979 had IC50 values against [3H]CGP 27492 binding of 8, 1.85, 69, 124, 326 and 1460 nM, respectively. In electrically-evoked [3H]GABA release from rat cortical slices, CGP 71982, CGP 71978, CGP 71980 and its enantiomer CGP 71979, antagonised GABA(B) autoreceptors with EC150 values of 2.5, 33, 181 and 474 nM, respectively. These compounds form a novel class of potent GABA(B) receptor antagonists.

Animals↗
PubMed2004

Chiral synthesis of (2S,3S)-2-(2-morpholin-2-yl-2-phenylmethoxy)phenol.

Resolution of (2RS,3RS)-2-[alpha-(2-methoxymethoxyphenoxy)phenylmethyl]morpholine, 11, with (+) mandelic acid led to the formation of (+)-(2S,3S)-2-[alpha-(2-methoxymethoxyphenoxy)phenyl methyl] morpholine (11a). Compound 11 was synthesized in seven steps from (2RS,3RS)-cinnamyl alcohol-2,3-epoxide (4), with an overall yield of 17%. Cleavage of the methoxymethyl group of the Fmoc derivative 12 with catalytic amounts of p-toluenesulfonic acid in methanol afforded (+)-(2S,3S)-2-(2-morpholin-2-yl-2-phenylmethoxy)phenol 2. The synthetic utility as well as the configuration of compound 2 has been demonstrated by converting (S,S)-2-(2-morpholin-2-yl-2-phenylmethoxy)phenol 2 to (2S,3S)-2-[alpha-(2-ethoxyphenoxy)phenylmethyl]morpholine (1) and (2S,3S)-2-(2-methoxyphenoxy) benzyl)morpholine (16), two potential norepinephrine reuptake inhibitors under clinical evaluation.

Antidepressive Agents↗
PubMed2000

High morpholine degradation rates and formation of cytochrome P450 during growth on different cyclic amines by newly isolated Mycobacterium sp. strain HE5.

Using morpholine as sole source of carbon, nitrogen and energy, strain HE5 (DSM 44238) was isolated from forest soil. The isolated strain was identified as a member of the subgroup of fast-growing Mycobacterium species as revealed by 16S rDNA analysis. An identity of 99.4% was obtained to Mycobacterium gilvum; however, the type strain was unable to utilize morpholine. A maximal growth rate of 0.17 h(-1) was observed at a morpholine concentration of 30 mM, 30 degrees C and pH 7.2. The substrate was tolerated at concentrations up to 100 mM. Besides morpholine, the strain utilized pyrrolidine, piperidine and proposed intermediates in morpholine metabolism such as glycolate, glyoxylate and ethanolamine. Degradation of morpholine, piperidine and pyrrolidine by resting or permeabilized cells was strictly dependent on the presence of oxygen. Addition of the cytochrome-P450-specific inhibitor metyrapone to the growth medium resulted in a significantly decreased growth rate if these cyclic amines were used as a substrate. Carbon monoxide difference spectra of crude extracts from cells grown on these substrates compared to spectra obtained for extracts of succinate-grown cells indicated that cytochrome P450 is specifically expressed during growth on the cyclic amines. These data indicated that a cytochrome-P450-dependent monooxygenase is involved in the degradation of the three cyclic amines.

Amines↗
PubMed1998

Morpholine degradation pathway of Mycobacterium aurum MO1: direct evidence of intermediates by in situ 1H nuclear magnetic resonance.

Resting Mycobacterium aurum MO1 cells were incubated with morpholine, a waste from the chemical industry. The kinetics of biodegradation was monitored by using in situ nuclear magnetic resonance (NMR). The incubation medium was directly analyzed by 1H NMR. This technique allowed the unambiguous identification of two intermediates of the metabolic pathway involved in the biodegradation process, glycolate and 2-(2-aminoethoxy)acetate. The latter compound, which was not commercially available, was synthesized, in three steps, from 2-(2-aminoethoxy)ethanol. Quantitative analysis of the kinetics of degradation of morpholine was performed by integrating the signals of the different metabolites in 1H-NMR spectra. Morpholine was degraded within 10 h. The intermediates increased during the first 10 h and finally disappeared after 20 h incubation. Assays of degradation were also carried out with glycolate and ethanolamine, hypothetical intermediates of the morpholine degradation pathway. They were degraded within 4 and 8 h, respectively. Until now, no tool for direct detection of intermediates or even morpholine has been available, consequently, only hypothetical pathways have been proposed. The approach described here gives both qualitative and quantitative information about the metabolic routes used in morpholine degradation by M. aurum MO1. It could be used to investigate many biodegradative processes.

Acetates↗
PubMed1989

Chronic morpholine exposure of rats.

The chronic toxicity and carcinogenic potential of morpholine were evaluated in 60 Sprague-Dawley rats/sex/group receiving morpholine at mean inhalation exposure concentrations of 0, 10, 50 and 150 ppm for 6 hr/day, 5 days/week, for 104 weeks. Survival, body weight gains, organ weights, hematology, and clinical chemistries were normal in exposed groups and comparable to those of the control animals. The incidences of palpable tissue masses and of histologically confirmed neoplasia were comparable among all groups, including the control groups, and were typical of the strain and age of the rats tested. In-life clinical examinations revealed increased incidences of irritation around the eyes and nares, chromadacryorrhea, and urine stains on the fur, predominantly in high-dose animals. Morpholine exposure was associated with corneal irritation seen by ophthalmoscopic examination and confirmed microscopically as keratitis limited to the highest exposure group. Irritation of the maxillary and nasoturbinates as indicated by infiltration of neutrophils, focal squamous metaplasia of the turbinate epithelium, and necrosis of the turbinate bone was observed in high-dose animals. Therefore, chronic exposure of rats to morpholine for 2 years at concentrations of 150 ppm or less revealed no carcinogenic potential or chronic systemic toxicity. Consistent with its known irritating properties, morpholine produced only local irritation, which was limited almost exclusively to high-dose animals.

Administration, Inhalation↗
PubMed1998

Degradation of morpholine by an environmental Mycobacterium strain involves a cytochrome P-450.

A Mycobacterium strain (RP1) was isolated from a contaminated activated sludge collected in a wastewater treatment unit of a chemical plant. It was capable of utilizing morpholine and other heterocyclic compounds, such as pyrrolidine and piperidine, as the sole source of carbon, nitrogen, and energy. The use of in situ 1H nuclear magnetic resonance (1H NMR) spectroscopy allowed the determination of two intermediates in the biodegradative pathway, 2-(2-aminoethoxy)acetate and glycolate. The inhibitory effects of metyrapone on the degradative abilities of strain RP1 indicated the involvement of a cytochrome P-450 in the biodegradation of morpholine. This observation was confirmed by spectrophotometric analysis and 1H NMR. Reduced cell extracts from morpholine-grown cultures, but not succinate-grown cultures, gave rise to a carbon monoxide difference spectrum with a peak near 450 nm, which indicated the presence of a soluble cytochrome P-450. 1H NMR allowed the direct analysis of the incubation medium containing metyrapone, a specific inhibitor of cytochrome P-450. The inhibition of morpholine degradation was dependent on the morpholine/metyrapone ratio. The heme-containing monooxygenase was also detected in pyrrolidine- and piperidine-grown cultures. The abilities of different compounds to support strain growth or the induction of a soluble cytochrome P-450 were assayed. The results suggest that this enzyme catalyzes the cleavage of the C-N bond of the morpholine ring.

Acetates↗
PubMed1984

A sensitive method for detecting in vivo formation of N-nitrosomorpholine and its application to rats given low doses of morpholine and sodium nitrite.

A method was developed to monitor the in vivo formation of N-nitrosomorpholine. N-Nitroso(2-hydroxyethyl)glycine, a major urinary metabolite of N-nitrosomorpholine, was quantified as its methyl ester-trimethylsilyl ether derivative, using gas chromatography with nitrosamine-specific detection. When the method was applied to rats, the in vivo formation of, or exposure to, as little as 0.6 micrograms of N-nitrosomorpholine could be quantified. The method was also applicable to human urine, with a detection limit of approximately 0.5 micrograms of N-nitroso(2-hydroxyethyl)glycine per 100-ml urine sample. The formation of N-nitrosomorpholine was measured in rats treated by gavage with a wide range of doses of morpholine and NaNO2. Depending on the dose, 0.5 to 12% of the morpholine was nitrosated. N-Nitrosomorpholine formation showed a high degree of variability among rats treated with a given dose of morpholine and NaNO2, but the levels of N-nitrosomorpholine formed were generally in agreement with expectations based on in vitro studies in which dependence on morpholine concentration multiplied by nitrite concentration squared has been established. The formation of N-nitrosomorpholine was also measured in rats administered a diet containing 50 ppm of morpholine and 1000 ppm of NaNO2, a regimen which has been previously shown to induce liver cell tumors in 58% of the animals. The mean daily formation of N-nitrosomorpholine under these conditions was estimated to be 0.88 +/- 0.59 mumol/rat (S.D.), which is high enough to account for the observed tumor incidence. The results of this study provide quantitative support for the assumption that in vivo formation of N-nitrosomorpholine leads to tumor development.

Animals↗
PubMed1994

Synthesis and effect on free radical processes on some substituted morpholine derivatives with potential biologic activity.

Since a number of 2-hydroxy(alkoxy)-2-phenyl-4(5,6)-(tri)alkyl-morpholines presented antioxidant and interesting biologic activity which may implicate free radical processes, some 2-hydroxy(alkoxy)-2-biphenyl-4-methyl-morpholine derivatives were prepared in an attempt to synthesize more potent antioxidants with interesting biologic action. The 2-hydroxy-2-biphenyl-4-methyl-morpholine was prepared by reacting the N-methyl-ethanolamine with the p-phenyl-phenacylbromide, the 2-hydroxy-derivative formed after spontaneous cyclisation gave the 2-alkoxy-2-biphenyl-4-methyl morpholines by an acid catalyzed ketal formation. The lipophilicity of the synthesized compounds was determined by the reversed phase TLC technique as RM values. The synthesized 2-biphenyl substituted morpholines were evaluated for their antioxidant activity on hepatic microsomal lipid peroxidation and on hydroxyl radical mediated oxidation of dimethylsulfoxide. The synthesized compounds were found to possess potent antioxidant activity. A possible mechanism was proposed for the antioxidant properties while lipophilicity was found not to be an important determinant of this property.

Animals↗
PubMed2002

Conformationally restrained analogues of sympathomimetic catecholamines. Synthesis and adrenergic activity of 5,6- and 6,7-dihydroxy-3,4-dihydrospiro[naphthalen-1(2H)-2',5'-morpholines].

The 5,6- (10a) and 6,7-dihydroxy-3,4-dihydrospiro[naphthalen-1(2H)-)-2',5'-morpholine](11a) and their N-isopropyl derivatives (10b and 11b) (DDSNMs), which can be viewed as the result of the combination of the structure of the 2-(3,4-dihydroxyphenyl)morpholine 5a or 5b (DPMs) with the structure of the corresponding 1-(aminomethyl)-5,6-dihydroxy- (8a or 8b) or 1-(aminomethyl)-6,7-dihydroxy-1,2,3,4-tetrahydro-1-naphthalen-ol (9a or 9b) (1-AMDTNs) were synthesised. The new compounds DDSNMs 10a,b and 11a,b were assayed for their alpha- and beta-adrenergic properties by means of binding experiments and functional tests and the results were compared with those obtained for catecholamines 1a, b and the previously described morpholine (5) and tetrahydronaphthalene (8, 9) derivatives. The affinity and activity indices thus obtained indicate in general a low ability of the new compounds 10 and 11 to interact with the alpha- and beta-adrenoceptors, which, in all cases, was lower than that of the corresponding morpholine (5) and tetrahydronaphthalene (8, 9) analogues.

Adrenergic Agonists↗
PubMed1984

Formation of N-nitrosomorpholine in mice treated with morpholine and exposed to nitrogen dioxide.

The possibility of N-nitrosomorpholine formation was investigated in mice treated with morpholine and then exposed to 45 p.p.m. nitrogen dioxide in an inhalation chamber for 2 h. Following this treatment, the mice were frozen and pulverized in liquid nitrogen and concentrated extracts from the powders of these animals were analyzed for N-nitrosomorpholine using a thermal energy analyzer interfaced to a gas chromatograph. The data indicate that nitrogen dioxide exposure causes the nitrosation of morpholine in vivo. Additional data show that significant levels of artifactually formed N-nitrosomorpholine are found in control animals that are treated with morpholine after exposure to nitrogen dioxide for 2 h unless a combination of L-ascorbic acid and d,1-alpha-tocopherol are used to inhibit nitrosation during the homogenization, extraction, and analysis of the samples. The need for both a lipid phase nitrosation blocker (d,1-alpha-tocopherol) and an aqueous phase nitrosation blocker (L-ascorbic acid) indicates that the nitrosation of morpholine occurs in both a lipid and an aqueous phase in vitro and therefore may occur in both a lipid and an aqueous environment in vivo. The data from this study also demonstrate the importance of adding suitable inhibitors of nitrosation, such as L-ascorbic acid and d,1-alpha-tocopherol to the extraction solution to prevent possible artifactual formation of N-nitrosomorpholine during the extraction and analysis of the samples.

Animals↗